PET avoids need for liver resection in colon cancer patients

Article

A multicenter prospective trial in the Netherlands has found that FDG-PET prevents unnecessary surgeries for one in six patients with metastatic colon cancer who undergo liver resection based on CT findings.

A multicenter prospective trial in the Netherlands has found that FDG-PET prevents unnecessary surgeries for one in six patients with metastatic colon cancer who undergo liver resection based on CT findings.

Dr. W.J.G. Oyen of Radboud University Nijmegen Medical Center and colleagues enrolled 75 surgical candidates randomly selected for assessment with CT alone, the standard imaging for recommending surgery, and another 75 who were evaluated with CT and FDG-PET. All 75 patients in the CT group underwent laparotomy compared to 70 in the PET group. Overall, surgeries for 34 (45%) and 21 (28%) patients performed on the basis of CT or CT plus PET, respectively, were considered futile. Disease recurred within six months in almost a third of patients in the CT-only group. Oyen presented results at the 2008 SNM meeting in New Orleans, Louisiana.

-By H.A. Abella

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.